Buchumschlag

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	María José García, Javier P. Gisbert, María Chaparro
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
von: María José García, et al.
Veröffentlicht: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
von: Matthias Lenfant, et al.
Veröffentlicht: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision?
von: L. A. A. P. Derikx, et al.
Veröffentlicht: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
von: Vibeke Strande, et al.
Veröffentlicht: (2024)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
von: María Chaparro, et al.
Veröffentlicht: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
von: Tomohiro Fukuda, et al.
Veröffentlicht: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply
von: Remo Panaccione
Veröffentlicht: (2024)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
von: Cristina Rubín de Célix, et al.
Veröffentlicht: (2025)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
von: David Bergman, et al.
Veröffentlicht: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively?
von: David Laharie
Veröffentlicht: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
von: Kyle Staller, et al.
Veröffentlicht: (2024)

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply
von: Marcus M. Mücke, et al.
Veröffentlicht: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
von: Dipesh H. Vasant, et al.
Veröffentlicht: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
von: Annalisa Schiepatti, et al.
Veröffentlicht: (2024)

A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis
von: Anthony Croft, et al.
Veröffentlicht: (2024)

Editorial: H. pylori Treatment—Old Ingredients in New Effective Regimens. Authors' Reply
von: Olga P. Nyssen, et al.
Veröffentlicht: (2025)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
von: Abhinav Vasudevan, et al.
Veröffentlicht: (2024)

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply
von: Matthias Lenfant, et al.
Veröffentlicht: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
von: Elliot B. Tapper, et al.
Veröffentlicht: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
von: María Chaparro, et al.
Veröffentlicht: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
von: Hyeyeon Hong, et al.
Veröffentlicht: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
von: C. M. Fernández‐Rodríguez, et al.
Veröffentlicht: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
von: Lukas Burghart, et al.
Veröffentlicht: (2024)

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
von: Ami D. Sperber, et al.
Veröffentlicht: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
von: Arta Aliu, et al.
Veröffentlicht: (2024)

Editorial: Quantity is important! Authors' reply
von: Marika Rudler, et al.
Veröffentlicht: (2024)

Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply
von: Nina Løn, et al.
Veröffentlicht: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply
von: Sagnik Biswas, et al.
Veröffentlicht: (2024)

Editorial: Shorter course of intravenous terlipressin in acute variceal bleeding—the promise, controversies and future directions. Author's reply
von: Sagnik Biswas, et al.
Veröffentlicht: (2024)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
von: Stephanie A. Vuijk, et al.
Veröffentlicht: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
von: S. K. Bansal, et al.
Veröffentlicht: (2024)

Letter: Enhancing gastric cancer prevention—The need for a comprehensive three‐tier emergency management strategy. Authors' reply
von: Irene Ligato, et al.
Veröffentlicht: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
von: Kyuwon Kim, et al.
Veröffentlicht: (2024)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data—Authors' reply
von: Rocío Ferreiro‐Iglesias, et al.
Veröffentlicht: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply
von: Andrea Martini, et al.
Veröffentlicht: (2024)

Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing
von: Tomohiro Fukuda, et al.
Veröffentlicht: (2024)